LK
Lawrence Otto Klein (Chief Executive Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Oruka Therapeutics, Inc. (ORKA). The largest single filing was $6.9M of ORKA (75,000 sh across 3 lots, as filed), executed Sep 1. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$11.6M
shares × price, as filed
Last traded
Nov 2
Filed Nov 2
Median ADV $139.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $11.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ORKARecent filings
ORKASALE
Oruka Therapeutics, Inc.
View filing →
$2.3M23,944 sh across 3 lots
Exec Nov 2
Filed Nov 2 · 5:46 PM ET ORKASALE Oruka Therapeutics, Inc. View filing → $2.1M
24,800 sh across 2 lots
Exec Oct 1
Filed Oct 2 · 7:54 PM ET ORKASALE Oruka Therapeutics, Inc. View filing → $235K
2,452 sh × $95.71
Exec Sep 15
Filed Sep 15 · 7:15 PM ET ORKASALE Oruka Therapeutics, Inc. View filing → $6.9M
75,000 sh across 3 lots
Exec Sep 1
Filed Sep 1 · 6:35 PM ET ORKASALE Oruka Therapeutics, Inc. View filing → $120K
1,729 sh × $69.69
Exec Jun 15
Filed Jun 15 · 5:30 PM ET